Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HILSNASDAQ:MENYSE:NNVCNASDAQ:TCDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHILSHillstream BioPharma$1.80+2.4%$1.43$0.19▼$2.65$31.73M3.081.39 million shs41,410 shsME23andMe$0.50-35.3%$0.50$0.53▼$10.81$13.36M1.191.44 million shs29.28 million shsNNVCNanoViricides$1.40+13.8%$1.43$0.94▼$2.55$22.50M0.91237,121 shs625,726 shsTCDATricida$0.13$0.09▼$13.85$6.01M0.2217.62 million shs31.13 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHILSHillstream BioPharma0.00%+34.51%+21.79%+27.84%-48.94%ME23andMe0.00%0.00%0.00%0.00%-93.63%NNVCNanoViricides0.00%-2.10%-7.89%+19.66%-18.60%TCDATricida0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHILSHillstream BioPharmaN/AN/AN/AN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AN/AN/AN/ANNVCNanoViricides0.3925 of 5 stars0.05.00.00.01.10.00.0TCDATricidaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHILSHillstream BioPharma 0.00N/AN/AN/AME23andMe 1.00SellN/AN/ANNVCNanoViricides 0.00N/AN/AN/ATCDATricida 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHILSHillstream BioPharmaN/AN/AN/AN/A$0.48 per shareN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21NNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ATCDATricidaN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHILSHillstream BioPharma-$8.47M-$0.72N/AN/AN/AN/A-188.44%-149.61%N/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/ANNVCNanoViricides-$8.29M-$0.70N/A∞N/AN/A-87.90%-78.69%N/ATCDATricida-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHILSHillstream BioPharmaN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ATCDATricidaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHILSHillstream BioPharmaN/A3.013.01ME23andMeN/A1.050.91NNVCNanoViricidesN/A3.442.47TCDATricidaN/A4.874.87Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHILSHillstream BioPharma13.36%ME23andMe36.10%NNVCNanoViricides10.30%TCDATricidaN/AInsider OwnershipCompanyInsider OwnershipHILSHillstream BioPharma30.24%ME23andMe26.32%NNVCNanoViricides4.60%TCDATricida35.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHILSHillstream BioPharma117.60 million12.28 millionNot OptionableME23andMe77026.83 million19.77 millionNot OptionableNNVCNanoViricides2016.07 million14.92 millionOptionableTCDATricida5755.67 million35.85 millionNot OptionableTCDA, HILS, NNVC, and ME HeadlinesRecent News About These CompaniesTricida CEO to Pay $14 Million in Class Suit Over Drug ProgressMarch 4, 2025 | news.bloomberglaw.comNPatrick G Enright's Net WorthMay 5, 2024 | benzinga.comSierraConstellation Partners Receives Industry Recognition for Work with TricidaFebruary 6, 2024 | finance.yahoo.comTricida Inc (TCDAQ)January 13, 2024 | es.investing.comEmerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseMay 30, 2023 | medscape.comMVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceApril 17, 2023 | news.google.comNMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalApril 17, 2023 | news.google.comNReal-time PCR as a Diagnostic Tool for Bacterial DiseasesApril 12, 2023 | medscape.comMChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalApril 10, 2023 | news.google.comNChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalApril 6, 2023 | news.google.comNTricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360March 24, 2023 | news.google.comNAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceMarch 14, 2023 | news.google.comNAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceMarch 14, 2023 | news.google.comNTricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360March 6, 2023 | news.google.comNTroubled Adamis To Merge With Private DMK, Focus On ... - ScripMarch 1, 2023 | news.google.comNRelease Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360February 27, 2023 | news.google.comNRenibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360February 21, 2023 | news.google.comNSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comFebruary 18, 2023 | news.google.comNTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comFebruary 18, 2023 | news.google.comNTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceFebruary 14, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeCostco at a Crossroads: Is the Next Move Higher or Lower?By Dan Schmidt | June 25, 2025View Costco at a Crossroads: Is the Next Move Higher or Lower?Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawBy Leo Miller | June 4, 2025View Constellation Energy and Meta Strike Nuclear Deal, Shares WhipsawTCDA, HILS, NNVC, and ME Company DescriptionsHillstream BioPharma NASDAQ:HILS$1.80 +0.04 (+2.41%) As of 06/27/2025Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-3215, an anti-HER2 monoclonal antibody candidate; and HSB-1940, a Quatrabody that is a proprietary IO biologic in development targeting PD-1. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.NanoViricides NYSE:NNVC$1.40 +0.17 (+13.82%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.41 +0.01 (+0.71%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Tricida NASDAQ:TCDATricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Snowflake Hits 52-Week High—Options Traders Bet on Further Rally Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
